|
Session 214: New Advances in Oncology Drug Discovery |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Hai Rao, Professor, South University of Science and Technology, China |
|
Co-Chair |
Dr. Georg Richter, Director, Institute of Pathology in Hameln, Germany |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Ubiquitin-mediated Proteolysis In Cancer Development And Drug Therapy Dr. Hai Rao, Professor, South University of Science and Technology, China |
|
09:00-09:25 |
Title: Cancer/testis Antigens MAGE-A and NY-ESO-1 in Breast Cancer Dr. Antonio Juretic, Professor, Department of Oncology, Zagreb University Hospital Center, Croatia |
|
09:25-09:50 |
Title: Melanoma and the Melanocortin 1 Receptor in an Australian Population Dr. David John Mackay Smith, University of Queensland, Australia |
|
09:50-10:15 |
Title: TBD Dr. Tian Xin, Director, Department of Hematology, Affliliated Children's Hospital of Kunming Medical University, China |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: Follow up with alfa-fetoprotein in HCC treated with TKIs Dr. Oriol Mirallas, Medical Oncology Department, Vall d'Hebron University Hospital, Spain |
|
10:55-11:20 |
Title: Uncommen Breast Cancer:Multifocal Invasive Ductal Breast Cancer with Osteoclast-like Giant Cells Dr. Georg Richter, Director, Institute of Pathology in Hameln, Germany |
|
11:20-11:45 |
Title: TBD Dr. Linda Friedman, Associate Professor, Department of cell biology and anatomy, New York Medical College, USA |
|
11:45-12:10 |
Speech Opportunity Available |
|
Session 224: Emerging Drug Screening Technology |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
Session 314: Emerging Drug Targets for Metabolic Disorders |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Serge Bottari, Professor, Faculty of Medicine and CHU Grenoble-Alpes, GREPI, TIMC-IMAG,UMR 5525 CNRS - UGA, France |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-08:55 |
Title: Homeostatic and Pathogenic Roles of GM3 Ganglioside Molecular Species in TLR4 Signaling in Obesity Dr. Jinichi Inokuchi, Professor and Chairman, Division of Glycopathlogy, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Japan |
|
08:55-09:15 |
Title: TBD Dr. Serge Bottari, Professor, Faculty of Medicine and CHU Grenoble-Alpes, GREPI, TIMC-IMAG,UMR 5525 CNRS - UGA, France |
|
09:15-09:35 |
Title: Brain-derived Neurotrophic Factor in Diabetes and Chemotherapy induced Peripheral Neuropathy |
|
09:35-09:55 |
Title: Brown Adipose Tissue – A New Therapeutic Target for Metabolic Disease Dr. Florian W. Kiefer, Associate Professor of Medicine, Clinical Division of Endocrinology and Metabolism, Department of Medicine, Vienna General Hospital, Medical University of Vienna, Austria |
|
09:55-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: RNA inhibition - A New Class of Medicines: The Story of Primary Hyperoxaluria Type 1 Dr. Yaacov Frishberg, Professor & Director, Division of Pediatric Nephrology, Shaare Zedek Medical Center, Israel |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Speech Opportunity Available |
|
Session 324: Emerging Kinase Targets and Kinase Inhibitor Discovery |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Kamil Paruch, Associate Professor, Department of Chemistry, Masaryk University, Czech Republic |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: Recently, We Have Discovered Highly Selective Inhibitors of Selected Non-routine Protein Kinases Dr. Kamil Paruch, Associate Professor, Department of Chemistry, Masaryk University, Czech Republic |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
Session 416: Inflammation and Immunological Diseases |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Yehuda Shoenfeld, Professor, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, Israel |
|
Co-Chair |
Dr. Dimitri F. Dimitriou, Chief Executive Officer, ImmuPharma plc, UK |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: Why We Develop Autoimmune Diseases; Hyper Stimulation of the Immune System- proves of Concept
Dr. Yehuda Shoenfeld, Professor, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, Israel |
|
09:25-09:50 |
Title: Novel Agents for Inflammatory and Immunological Diseases Dr. Mark Chiu, President, Tavotek Biotherapeutics, USA |
|
09:50-10:15 |
Title: Clinically Important Neutralizing Anti-drug Antibodies Detected with an in-house Competitive ELISA Dr. Sasa Cucnik, Assistant Professor, Department of Rheumatology, University medical centre Ljubljana, The Academic and Research Network of Slovenia, Slovenia |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: Challenges in Drug Development in Immune Diseases Dr. Dimitri F. Dimitriou, Chief Executive Officer, ImmuPharma plc, UK |
|
10:55-11:20 |
Title: Short Term Effect of Outdoor Mould Spore Exposure Non Prescribed Allergy Medication Sales in France (Paris, Lyon, and Bordeaux) Dr. Denis Caillaud, Head, Pulmonary Department, CHU Clermont-Ferrand, Université Clermont Auvergne, France |
|
11:20-11:45 |
Title: The Microbiome as a Reservoir of Therapeutic Solutions in Immune-mediated Inflammatory Diseases Dr. Karine ROGET, Chief Scientific Officer, Nexbiome Therapeutics, France |
|
11:45-12:10 |
Title: Clinical Data on an Essential Biosimilar: Promising Results in Phase I and Phase III Studies of CinnoRA Dr. Ahmadreza Jamshidi, Specialist, Aryogen, Iran |
|
Session 417: Digestive System Diseases |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Keynote Speech Title: Management of Hemostasis in Acute and Chronic Liver Disease Dr. Jun Teruya, Professor, Baylor College of Medicine, USA |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Title: TBD Dr. Zheng Lei Xu, Associate Professor, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, China |
|
09:50-10:15 |
Title: Phenotypic and Genotypic Features of Non-alcoholic Fatty Liver Disease Dr. Olena Kolesnikova, Research Director, Department of Hepatology, Government Institution L.T. Malaya Therapy, National Institute of NAMS of Ukraine, Ukraine |
|
10:15-10:30 |
Coffee Break |
|
Session 418: Orphan and Rare Diseases & Other Diseases |
|
|
Day 3: Morning, May 13, 2022 |
|
|
Chair |
Dr. Marlene E. Haffner, President and CEO, HaffnerAssociates, LLC , USA |
|
Co-chair |
Dr. Silvia Gartner, Coordinator, Pediatric Cystic Fibrosis Center; Principal Investigator of ECFS-CTN Barcelona Center, Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d´Hebron, Spain |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Measuring CFTR Function in Respiratory Epithelial Cell Cultures: Step to Individualize Treatments in Cystic Fibrosis? Dr. Joerg Grosse-Onnebrink, Head of Pediatric Pneumology, University Children’s Hospital Münster, Germany |
|
09:00-09:25 |
Title: TBD Dr. Marlene E. Haffner, President and CEO, HaffnerAssociates, LLC , USA |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Title: The Importance for Early Diagnosis and Treatment in Cystic Fibrosis Dr. Silvia Gartner, Coordinator, Pediatric Cystic Fibrosis Center; Principal Investigator of ECFS-CTN Barcelona Center, Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d´Hebron, Spain |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Title: TBD Dr. Sylvie Pucheu, Founder and CSO, CILcare, France |
|
11:20-11:45 |
Title: Formulation Strategies for Rare Diseases Dr. Alessandra Rossi, Assistant Professor, Food and Drug Department, University of Parma, Italy |
|
11:45-12:10 |
Title: Sexuality, Intimacy and The Brain in Older Age Drs. Els Messelis, Gerontologist, Lachesis, Belgium |
Session 423: Catch the New Wave of Protein and Peptide Therapy Day 3: Morning, May 13, 2022 Dr. Kiyoshi Nokihara, Founder CEO and CSO, HiPep Laboratories, Japan Co-Chair Dr. Ved Srivastava, Vice President of Peptide Chemistry, Intarcia Therapeutics, USA Time 13:30-13:35 Chair's Introduction 13:35-14:00 Title: Novel Angiogenic Peptides for Regenerative Medicine and Their Action Mechanisms Dr. Kiyoshi Nokihara, Founder CEO and CSO, HiPep Laboratories, Japan 14:00-14:25 Title: New Wave of Peptide Therapy - Discovery to Commercialization Dr. Ved Srivastava, Vice President of Peptide Chemistry, Intarcia Therapeutics, USA 14:25-14:50 Title: Affibody-mediated HER3-targeting for Cancer Therapy Dr. Stefan Stahl, Professor, Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Sweden 14:50-15:15 Title: Peptides for Drug Delivery Applications Dr. Kalina Hristova, Professor of Materials Science and Engineering and Biomedical Engineering, Institute for NanoBioTechnology, Johns Hopkins University, USA 15:15-15:30 Coffee Break 15:30-15:55 Title: Evaluation of the Efficacy of Peptide Targeting Chemotherapy for Different Cancers Dr. Chin-Tarng Lin, Emeritus Professor, College of Medicine, National Taiwan University, Taiwan, China 15:55-16:20 Title: TBD Mr. Habib Torfi, Chief Executive Officer Invitrx Therapeutics Inc., USA 16:20-16:45 Title: Effects of PACAP on Dry Eye Symptoms and Possible Use for Therapeutic Application Dr. Seiji Shioda, Professor, Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Japan 16:45-17:10 Speech Opportunity Available
Chair
|
Session 215: Innovations in Neuroscience Drug Discovery |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Zhenghong Qin, Professor, Soochow University School of Pharmaceutical Science, China |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: Could NADPH be a Drug Candidate for Stroke? Dr. Zhenghong Qin, Professor, Soochow University School of Pharmaceutical Science, China |
|
14:25-14:50 |
Title: Audiogenic Seizures and Anticonvulsants Dr. Inga Poletaeva, Professor, Moscow State University, Russia |
|
14:50-15:15 |
Title: Brain Simulation Science and Technology for Drug Discovery Dr. Michele Migliore, Professor, Institute of Biophysics, National Research Council, Palermo, Italy |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Mitophagy in Neurons and Astrocytes Promotes Cell Survival and Longevity Dr. Eduard Korkotian, Senior Scientist, Department of Neurobiology, Weizmann Institute of Science, Israel |
|
15:55-16:20 |
Title: TBD Dr. Menahem Segal, Emeritus Professor, Department of Neurobiology, The Weizmann Institute, Israel |
|
16:20-16:45 |
Speech Opportunity Available |
|
16:45-17:10 |
Speech Opportunity Available |
|
Session 225: Computer-aided Drug Discovery and Development |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Jian Yang, Senior Director, Digital Heath, Eli Lilly and Company, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: Applied Machine Learning in Late Stage BioProcess Development Dr. Donald (Donnie) Palahnuk, Vice President, TopAlliance Biosciences Inc., China |
|
14:25-14:50 |
Title: Lessons Learned on Rolling out of Risk Based Quality Management System for a Large Series of Studies |
|
14:50-15:15 |
Title: Digital Biomarker for Drug Development Dr. Jian Yang, Senior Director, Digital Heath, Eli Lilly and Company, USA |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Advanced Data Integrate and Machine Learning to Accelerate Ab discovery, Design and Down Selection Dr. Yiqun Li, Head of IT Lilly Biotechnology Center, Eli Lilly and Company, USA |
|
15:55-16:20 |
Speech Opportunity Available |
|
16:20-16:45 |
Title: TBD Dr. Matin Pirouz, Assistant Professor, Department of Computer Science, College of Science and Mathematics, California State University, USA |
|
16:45-17:10 |
Speech Opportunity Available |
|
Session 315: Infectious Disorders Drug Targets |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: TBD Dr. Matyas Sandor, Professor, Department of Pathology, University of Wisconsin-Madison, USA |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: Predictors of COVID 19 Infection and Disease Progress Dr. Refat A Sadeq, Head, Department of Medical Microbiology, Port Said University, Egypt |
|
15:15-15:30 |
Coffee Break |
|
Session 325: New Insights into Small Molecule Drug Discovery |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Hartmut Beck, Science Fellow, Medicinal Chemistry, Bayer AG, Germany |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: Discovery of Molidustat, a Small Molecule Oral HIF-PH Inhibitor for the Treatment of Renal Anemia Dr. Hartmut Beck, Science Fellow, Medicinal Chemistry, Bayer AG, Germany |
|
14:25-14:50 |
Title: Development of Luminescent Metal Complexes to Induce and Study Programmed Cell Death in Cancer Cells Dr. Shin Aoki, Professor, Faculty of Pharmaceutical Sciences; Vice Dean of Research Institute for Science and Technology (RIST), Tokyo University of Science, Japan |
|
14:50-15:15 |
Title: Development of Small-molecule HPK1 Inhibitors to Unleash Exhausted Tumor T Cells Dr. Nagaraj Gowda, General Manager & Head, In Vitro Biology-NCE Research, Glenmark Pharmaceuticals Ltd., India |
|
15:15-15:30 |
Coffee Break |
|
Session 419: Pharmacovigilance, Drug Safety and Risk Management |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Dave A Dongelmans, Amsterdam University Medical Centers, the Netherlands |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: Improving Medication Safety in the Intensive Care by Identifying Relevant Drug-Drug Interactions Dr. Dave A Dongelmans, Amsterdam University Medical Centers, the Netherlands |
|
14:25-14:50 |
Title: Medical Cannabis: Toward an Understanding of University Student Attitudes, Beliefs and Knowledge for Education Purposes Dr. Richard Isralowitz, Professor, Director of Regional Alcohol and Drug Abuse Resources (RADAR) Center, Ben Gurion University, Israel |
|
14:50-15:15 |
Title: TBD Dr. Lilly Li, Associate Professor, Institute of Textile and Clothing, The Hong Kong Polytechnic University, Hong Kong, China |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Pharmacovigilance Outsourcing and the importance of Pharmacovigilance Agreements
Dr. Andrew Bond, Associate Director, Pharmacovigilance Agreement, CSL, USA |
|
15:55-16:20 |
Title: Master Documentation and Records in the Clinical Data Management Dr. Hualong Sun, General Manager, Meta Clinical Technology Co. Ltd; Chief Operating Officer, Beijing Clinical Service Center, China |
|
16:20-16:45 |
Title: Intrathecal Morphine Risks and Benefit
Dr. Aart Jan W Teunissen, Anesthesiologist-Pain Specialist, Anesthesiology, Maasstadziekenhuis, The Netherlands |
| 16:45-17:10 | Speech Opportunity Available |
|
Session 424: Cell and Gene Therapy: Translational Development and Clinical Applications |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Asif M. Paker, Vice President, Clinical Development, SwanBio Therapeutics, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Speech Opportunity Available |
|
13:55-14:15 |
Title: TBD Dr. Jeffrey Hung, Chief Commercial Officer, GM of cGMP Business, Vigene Biosciences, USA |
|
14:15-14:35 |
Title: Developing Gene Therapy for a Non-fatal Slowly Progressive Disease Affecting CNS Dr. Asif M. Paker, Vice President, Clinical Development, SwanBio Therapeutics, USA |
|
14:35-14:55 |
Title: Bioholographic Drugs for Restoring the Wave Optics in Chromosomes in the Case of Autoimmune Damage by SARS-CoV-2 Dr. Irene Caesar, President, Wave Genome LLC, USA |
|
14:55-15:10 |
Coffee Break |
|
15:10-15:30 |
Title: The Use of Human Cord Blood Mononuclear Cells for the Treatment of Spinal Cord Injury: From Experiment to Clinical Applications Dr. Sergey I. Ryabov, Leading Researcher, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation Search, Russia |
|
15:30-15:50 |
Title: Retinal Pigment Epithelium for Treatment of Macular Degeneration: from Discovery to First in Human Clinical Trials Dr. Irina Klimanskaya, Senior Director of Translational Development, Astellas Institute for Regenerative Medicine, USA |
|
15:50-16:10 |
Title: Drivers and Challenges of the Intersection of Gene Therapies with Precision Medicine Dr. Oscar Segurado, Chief Medical Officer, ASC Therapeutics, USA; Tenured Professor of Immunology, Universidad de León, Spain |
|
16:10-16:30 |
Title: TBD Dr. Kalyan K. Ganguly, Scientist, Indian Council of Medical Research, India |
|
16:30-16:55 |
Title: Bone Marrow-derived Mesenchymal Stem Cells Improve Cognitive Impairment in an Alzheimer's Disease Model by Increasing the Expression of MicroRNA-146a in Hippocampus Dr. Masako Nakano, Research Associate, Sapporo Medical University School of Medicine, Japan |
|
Session 425: Milan Systemic Family Therapy Approach on Drugs |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Pietro Barbetta, Professor of Psychodynamic Theories, University of Bergamo; Director, Milan Center for Family Therapy (Milan), Italy |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: L’Homme Machine: How the Culture of Drugs Helps the Cure for Going Worse, a Clinical Case Dr. Pietro Barbetta, Professor of Psychodynamic Theories, University of Bergamo; Director, Milan Center for Family Therapy (Milan), Italy |
|
14:00-14:25 |
Title: Systemic Approach in Benzodiazepines Addiction in Healthcare Settings: A Case Report Dr. Michele Mattia, Lecture, San Raffaele University (Milan), Italy |
|
14:25-14:50 |
Title: Harm Reduction and Shared Hypotization of the Games Played Dr. Umberta Telfener, Adjunct Faculty, University of Roma La Sapienza, Italy |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
|
Session 432: Application of Natural Products |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Dr. Yong Zhu, Associate Professor, Yale University School of Public Health, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: The Concept of Zeolite in Fundamental Research and Medical Application Dr. Wilfried Dathe, External Consultant and Head of Medical Research, Heck Bio-Pharma GmbH, Germany |
|
14:25-14:50 |
Title: Therapeutic Use of Valeric Acid in Cancer Treatment: A Preclinical Study Dr. Yong Zhu, Associate Professor, Yale University School of Public Health, USA |
|
14:50-15:15 |
Title: Anthocyanins Interfere in the Homeostasis of Bilirubin and Bile Acids in the Blood: Implications for the Metabolic Syndrome Dr. Sabina Passamonti, Assistant Professor, Universitau di Trieste, Italy |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Comparing the Response of Narrowband UVB Therapy to Heliotherapy and a Topical Application of Lecithin and the Amino Acid L Tryptophan Dr. Rowland Noakes, Consultant Dermatologist, Terrace Dermatology, Australia |
|
15:55-16:20 |
Title: Microbial Assisted Geo-polymer Construction Material - An Approach towards Green House to Green Home Dr. Brajadulal Chattopadhyay, Professor & Coordinator of Condensed Matter Physics Research Center (CMPRC), Department of Physics, Jadavpur University, India |
|
16:20-16:45 |
Title: Medication Rules of Anti-tumor Formulas Containing Marine Chinese Dr. Jiang Lin, Professor, Guangxi University of Chinese Medicine, China |
|
16:45-17:10 |
Title: Natural Anthraquinones as Primary and Complementary Therapeutics in the Treatment of Colorectal Cancer Dr. Alexander Sougiannis, Medical University of South Carolina, USA |
|
Session 444: Pharma Policy, Regulations and Marketing Trends |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Mr. James Stumpff, Principal Consultant, PAREXEL, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: The Direction of Pharma Policy, How a Global Pandemic and Customized Medicine Have Driven Convergence in Healthcare Ecosystem Entities Mr. Stan Russell, Vice President, Site Head of Quality, Sebela Pharmaceuticals Inc., USA |
|
14:25-14:50 |
Title: Benefits of a Successful Technology Transfer Program Mr. James Stumpff, Principal Consultant, PAREXEL, USA |
|
14:50-15:15 |
Title: TBD Dr. Andreia Collier, Senior Vice President, Regulatory Affairs - Europe, North America, and Global New Molecular Entities, Glenmark Pharmaceuticals INC, USA |
|
15:15-15:30 |
Coffee Break |
|
Stream 5: Young Scientist Forum |
|
|
Day 3: Afternoon, May 13, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study Dr. Melanie Dechamps, Cardiovascular Intensive Care Unit, St Luc University Hospital, Belgium |
|
14:00-14:25 |
Title: TBD Ms. Maria Elena Barone, Research Student, Institute of Technology Sligo, Ireland |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
© 2003-2022 All rights reserved by BITeomics |